Bayer will transfer a large part of its small molecule research unit based in Berlin, Germany, to Nuvisan, an international service provider for clinical studies, laboratory services, and contract manufacturing.
The Berlin-based research unit with around 400 workplaces comprises of a fully operational team specialized in small molecule research. Bayer will retain significant research activities in Berlin which remains the headquarters for the company’s Pharmaceuticals Division and one of its major global research sites.
The partnership will lay the foundation for a new research entity that will be established by Nuvisan in Berlin. The transaction is expected to close mid of 2020 subject to the successful completion of the consultation process with the employee representatives and the preparations for taking over the research activities.